GlassScriptPhysician profile
Muhammad T Malik
NPI 1528487816
$10,062.59
in general payments reported to CMS, 2019-2025
26 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.91 · 2021: $4,809 · 2022: $3,381 · 2023: $1,297 · 2024: $358 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $3,340.81 | 2021-2023 | Ocrevus |
| Horizon Therapeutics Plc | $1,871.63 | 2022-2023 | Uplizna |
| Janssen Global Services, LLC | $1,320.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $1,119.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $651.48 | 2022-2025 | |
| Biogen, INC. | $359.14 | 2021-2023 | Vumerity, Plegridy, Tysabri |
| Emd Serono, INC. | $347.81 | 2019-2023 | Mavenclad |
| Abbvie INC. | $305.57 | 2022-2025 | |
| Genzyme Corporation | $147.93 | 2021-2023 | |
| Tg Therapeutics, INC. | $113.40 | 2025 | |
| Sk Life Science, INC. | $65.58 | 2022-2023 | |
| Genentech USA, INC. | $65.05 | 2022-2023 | Ocrevus |
| Harmony Biosciences LLC | $51.22 | 2022 | |
| Amneal Pharmaceuticals LLC | $41.26 | 2022-2023 | Rytary |
| Astrazeneca Pharmaceuticals LP | $32.80 | 2024 | Andexxa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $31.44 | 2023 | Zeposia |
| Neurocrine Biosciences, INC. | $26.76 | 2022 | |
| Eisai INC. | $24.89 | 2023 | |
| Ucb, INC. | $24.12 | 2023 | Briviact |
| Csl Behring | $23.53 | 2022 | |
| Pfizer INC. | $18.13 | 2023 | |
| Almatica Pharma LLC | $18.05 | 2023 | Gralise |
| Biohaven Pharmaceutical Holding Company LTD. | $17.92 | 2022 | |
| Livanova USA, INC. | $17.19 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $14.16 | 2022 | |
| Avion Pharmaceuticals | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.